Literature DB >> 15570298

Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment.

Emilio Iannitto1, Emanuele Ammatuna, Claudio Tripodo, Carla Marino, Giuseppina Calvaruso, Ada Maria Florena, Giuseppe Montalto, Vito Franco.   

Abstract

Primary hepatic lymphoma is a rare but well-defined lymphoma entity that often pursues an aggressive clinical course. Most cases have been described in hepatitis C virus (HCV)-related chronic liver disease patients. Although anthracycline-based chemotherapy has been reported to be highly effective, the best therapeutic strategy has not been defined yet. The prognosis is dismal especially in patients treated with chemotherapy alone or when an advanced liver disease is present. Herein, we describe a case of primary hepatic large B-cell non-Hodgkin's lymphoma, in a patient with HCV chronic infection. After a minor response with eight cycles of CHOP chemotherapy, a complete and sustained remission was obtained with alpha-interferon at the daily dose of 3 MU. HCV-RNA clearance pace from the blood almost paralleled the response of the lymphoma and both diseases went in remission within 1 year of therapy. The possible place of alpha-Interferon in the treatment of primary hepatic lymphoma is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570298     DOI: 10.1038/sj.thj.6200408

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


  8 in total

Review 1.  [Malignant lymphomas of the liver: new diagnostic algorithms].

Authors:  T Longerich; P Schirmacher; H P Dienes; H Stein; C Loddenkemper
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

2.  HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution.

Authors:  Souichi Shiratori; Yutaka Tsutsumi; Takahito Kawamura; Kazuhiro Kudo; Norihiko Shimoyama; Nobuo Masauzi; Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Int J Hematol       Date:  2008-03-06       Impact factor: 2.490

Review 3.  Non-Hodgkin lymphoma and hepatitis C: where we are and what next?

Authors:  Mihály Sulyok; Mihály Makara; Eszter Újhelyi; István Vályi-Nagy
Journal:  Pathol Oncol Res       Date:  2014-10-02       Impact factor: 3.201

Review 4.  Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment.

Authors:  Carlo Visco; Silvia Finotto
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

5.  Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma.

Authors:  Jeff Hosry; Parag Mahale; Francesco Turturro; Roberto N Miranda; Minas P Economides; Bruno P Granwehr; Harrys A Torres
Journal:  Int J Cancer       Date:  2016-08-18       Impact factor: 7.396

Review 6.  Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.

Authors:  Luca Arcaini; Michele Merli; Stefano Volpetti; Sara Rattotti; Manuel Gotti; Francesco Zaja
Journal:  Clin Dev Immunol       Date:  2012-08-26

7.  Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis.

Authors:  Mohamed Abd El-Fattah
Journal:  J Clin Transl Hepatol       Date:  2017-05-14

8.  Progressive visceral leishmaniasis misdiagnosed as cirrhosis of the liver: a case report.

Authors:  Lydia Giannitrapani; Maurizio Soresi; Emanuele La Spada; Claudio Tripodo; Giuseppe Montalto
Journal:  J Med Case Rep       Date:  2009-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.